Metronidazole Market Report 2026

The metronidazole market size has grown strongly in recent years. It will grow from $0.61 billion in 2025 to $0.65 billion in 2026 at a compound annual growth rate (CAGR) of 5.5%. The growth in the historic period can be attributed to high incidence of bacterial and protozoal infections, long-standing clinical efficacy, broad inclusion in essential medicines lists, expansion of hospital antibiotic use, growth in surgical procedures.

The metronidazole market size is expected to see strong growth in the next few years. It will grow to $0.8 billion in 2030 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to rising global infection burden, increasing hospital admissions, sustained demand for affordable antibiotics, expansion of outpatient antimicrobial therapy, growth in emerging healthcare markets. Major trends in the forecast period include widespread use in anaerobic bacterial infections, growing demand for broad-spectrum antimicrobials, expansion of topical and oral formulations, increased use in gynecological and gastrointestinal infections, rising preference for cost-effective generic antibiotics.

The rising prevalence of bacterial infections is poised to boost the metronidazole market in the years ahead. Bacterial infections occur when harmful bacteria proliferate within the body. This trend stems from issues like antibiotic resistance, shifting environmental conditions, and growing numbers of people with weakened immune systems. Metronidazole attacks bacterial DNA, inflicting damage that prevents replication and dissemination. As a result, it proves highly effective against anaerobic bacteria and select protozoal infections, curbing bacterial proliferation and resolving the infection. For instance, in November 2025, the UK Health Security Agency - a UK government body - reported that cases of antibiotic-resistant bacteraemia, a dangerous bloodstream infection caused by bacteria, climbed 9.3% from 2023 levels, from 18,740 cases to 20,484 in 2024. Thus, the surge in bacterial infections will fuel expansion in the metronidazole market.

Major companies in the metronidazole market are prioritizing the development of innovative products, like ready-to-use oral liquids, to boost patient compliance - particularly for individuals who struggle with swallowing tablets or need simpler dosing for infection treatment. These ready-to-use oral liquids are pre-made liquid medications that require no additional preparation or mixing prior to use, offering significant convenience. For example, in November 2023, Kesin Pharma Corporation, a US-based specialty pharmaceutical firm, revealed that the Food and Drug Administration (FDA) had approved LIKMEZ (metronidazole) oral suspension, 500 mg/5 mL. This innovative version of a widely used antibiotic aims to enhance patient adherence and is indicated for trichomoniasis and anaerobic bacterial infections in adults, as well as amebiasis in adults and pediatric patients. LIKMEZ comes as a strawberry peppermint-flavored suspension in a 200 mL bottle, featuring a 24-month shelf life without the need for refrigeration.

In April 2023, Marksans Pharma, an Indian pharmaceutical company, bought a manufacturing site from Teva Pharmaceutical Industries for an undisclosed sum. This purchase positions Marksans to potentially double its current production capacity from 8 billion units annually. Teva Pharmaceutical Industries, an Indian pharmaceutical firm, produces metronidazole tablets.

Major companies operating in the metronidazole market are Pfizer Inc., Merck & Co. Inc., Abbott Laboratories, Fresenius Kabi AG, Baxter International Inc., Sandoz Group AG, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Cipla Limited, Dr. Reddy's Laboratories Ltd., Lupin Pharmaceuticals Inc., Zydus Lifesciences, YiChang HEC ChangJiang Pharmaceutical Co. Ltd., Aarti Drugs Ltd., Unichem Laboratories, Cosette Pharmaceuticals Inc., Saptalis Pharmaceuticals LLC, Huanggang Saikang Pharmaceutical Co. Ltd., Kesin Pharma, Hubei Hongyuan Pharmaceutical Technology Co. Ltd., Huanggang Yinhe Aarti Pharmaceutical Co. Ltd., Higgs Healthcare.

Asia-Pacific was the largest region in the metronidazole market in 2025. The regions covered in the metronidazole market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the metronidazole market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the metronidazole market by raising the cost of imported APIs and pharmaceutical excipients used in both oral and intravenous formulations. These impacts are most visible in hospital pharmacies and retail distribution channels, where pricing sensitivity and supply reliability are important. Developing regions have been particularly affected due to higher dependence on imported antibiotic inputs. Rising tariff related expenses have influenced procurement planning, inventory management, and treatment affordability. On the positive side, tariffs have supported domestic antibiotic manufacturing, expanded local production capacity, and reduced long term reliance on imports.

The metronidazole market research report is one of a series of new reports that provides metronidazole market statistics, including metronidazole industry global market size, regional shares, competitors with a metronidazole market share, detailed metronidazole market segments, market trends and opportunities, and any further data you may need to thrive in the metronidazole industry. This metronidazole market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Metronidazole serves as an antibiotic and antiprotozoal medication for treating bacterial and parasitic infections. It functions by entering microbial cells, where enzymes from bacteria and protozoa reduce it, producing reactive nitrogen species. These reactive compounds harm DNA, resulting in strand breaks and blocking nucleic acid synthesis, which ultimately interferes with replication and transcription to cause cell death.

The primary forms of metronidazole include tablets, capsules, intravenous (IV) solutions, topical creams or ointments, and additional variants. Metronidazole tablets serve as oral treatments for bacterial and parasitic infections, providing prolonged action and convenient, reliable care for outpatients. They find use across diverse areas like bacterial infections, parasitic infections, gynecological conditions, surgical prevention, and more, and reach patients via multiple channels such as hospital pharmacies, retail pharmacies, online pharmacies, and others. This medication supports various end-users, including hospitals, clinics, homecare settings, and beyond.

The metronidazole market consists of sales of oral suspension, suppositories, and gel. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.